Ken Drazan, ArsenalBio CEO

On fi­nal dash to the clin­ic, Ar­se­nal­Bio hauls in $220M for 'mod­u­lar' cell ther­a­py ap­proach

If Ar­se­nal­Bio does it right, its first CAR-T can­di­date — a po­ten­tial treat­ment for ovar­i­an can­cer — will be in the clin­ic lat­er this year.

And a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.